WARMINSTER, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”) is a clinical-stage biopharmaceutical company, Leveraging its extensive virology expertise to develop novel therapeutics targeting specific viral diseases, it was announced today that the Arbutus management team will attend and host one-on-one sessions at the following investor conferences:
HC Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference: The official demonstration will be held on October 25, 2023 at 4:30 pm ET
To view a live webcast of the presentation, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available for a limited time on the Arbutus website following the event.
About Yangmei
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company that leverages its broad virology expertise to identify and develop novel therapies with unique mechanisms of action that can be combined to treat chronic B. Provides functional cure for patients with hepatitis virus (cHBV)). ). We believe that the keys to successfully developing a functional cure include inhibiting HBV DNA, reducing surface antigens and enhancing HBV-specific immune responses. Our pipeline of proprietary compounds developed in-house includes the RNAi therapeutic imdusiran (AB-729) and the oral PD-L1 inhibitor AB-101. Imdusiran is the only RNAi that has generated meaningful clinical data demonstrating its effects on both surface antigen reduction and reawakening of HBV-specific immune responses. Imdusiran is currently undergoing two Phase 2a combination clinical trials. AB-101 is currently being evaluated in Phase 1a/1b clinical trials. We are also exploring oncology applications for our internal PD-L1 portfolio. For more information, please visit www.arbutusbio.com.
contact information
Investors and media
Lisa M. Cappellelli
Vice President of Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
